Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

Lassa virus can cause haemorrhagic fever for which no specific treatment currently exists. Here the authors have cloned 113 monoclonal antibodies from the survivors of Lassa infection and show that the majority of neutralizing antibodies target a complex of GP1 and GP2 viral proteins.

Bibliographic Details
Main Authors: James E. Robinson, Kathryn M. Hastie, Robert W. Cross, Rachael E. Yenni, Deborah H. Elliott, Julie A. Rouelle, Chandrika B. Kannadka, Ashley A. Smira, Courtney E. Garry, Benjamin T. Bradley, Haini Yu, Jeffrey G. Shaffer, Matt L. Boisen, Jessica N. Hartnett, Michelle A. Zandonatti, Megan M. Rowland, Megan L. Heinrich, Luis Martínez-Sobrido, Benson Cheng, Juan C. de la Torre, Kristian G. Andersen, Augustine Goba, Mambu Momoh, Mohamed Fullah, Michael Gbakie, Lansana Kanneh, Veronica J. Koroma, Richard Fonnie, Simbirie C. Jalloh, Brima Kargbo, Mohamed A. Vandi, Momoh Gbetuwa, Odia Ikponmwosa, Danny A. Asogun, Peter O. Okokhere, Onikepe A. Follarin, John S. Schieffelin, Kelly R. Pitts, Joan B. Geisbert, Peter C. Kulakoski, Russell B. Wilson, Christian T. Happi, Pardis C. Sabeti, Sahr M. Gevao, S. Humarr Khan, Donald S. Grant, Thomas W. Geisbert, Erica Ollmann Saphire, Luis M. Branco, Robert F. Garry
Format: Article
Language:English
Published: Nature Publishing Group 2016-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms11544

Internet

https://doi.org/10.1038/ncomms11544

Similar Items